Behind the Bell: Aldeyra Therapeutics

Published

We are joined by Todd Brady, CEO at Nasdaq-listed Aldeyra Therapeutics, on Aldeyra's 5 year listing anniversary.

Nasdaq Watch

See what's playing at Nasdaq

Watch Now